Persistent Correlation of Ghrelin Plasma Levels with Body Mass Index Both in Stable Weight Conditions and during Gastric-bypass-induced Weight Loss by Ybarra, J. et al.
RESEARCH ARTICLE
Persistent Correlation of Ghrelin Plasma Levels with Body
Mass Index Both in Stable Weight Conditions and during
Gastric-bypass-induced Weight Loss
J. Ybarra & E. Bobbioni-Harsch & G. Chassot &
O. Huber & Ph. Morel & F. Assimacopoulos-Jeannet &
A. Golay
Received: 22 July 2008 /Accepted: 6 October 2008 /Published online: 31 October 2008
# Springer Science + Business Media, LLC 2008
Abstract
Background Studies done on serial changes in plasma
ghrelin levels after gastric bypass (GBP) have yielded
contrasting results since decreased, unchanged, or increased
levels have been reported in the literature. This study
investigates whether or not GBP has an inhibitory effect on
fasting ghrelin levels independently of weight loss.
Methods Fasting ghrelin levels were measured in 115 stable
body weight females, classified as normal body weight
(NW; body mass index (BMI)<25 kg/m2), overweight
(OW; BMI 25–30 kg/m2), and obese subjects, divided in
three subgroups with increasing BMI (BMI 30–40 kg/m2;
BMI 40–50 kg/m2; BMI >50 kg/m2).
Results Each obese subgroup showed significantly lower
ghrelin levels as compared to both NW (p<0.0001) and
OW subjects (p<0.05 or 0.005); however, no significant
differences were observed within the three obese subgroups.
Forty-nine obese patients underwent a GBP. Plasma ghrelin,
measured at 3, 6, and 12 months after GBP, significantly
increased from the sixth month on (p<0.0001). When
patients were classified, at each postoperative time point,
according to their actual BMI, ghrelin was significantly
(p=0.0002) related to postoperative BMI and not signifi-
cantly different from ghrelin measured in stable body
weight conditions.
Conclusions Fasting ghrelin displays an inversely significant
correlation with BMI in both stable body weight conditions
and after GBP. No evidence was found that GBP had an effect
on fasting ghrelin levels, independent of weight loss.
Keywords Ghrelin . BMI . Obesity . Body weight loss .
Gastric bypass
Introduction
Obesity is becoming a major public health problem world-
wide [1] and most dietary and/or pharmacologic approaches
end up in failure and/or recidivism. Hence, weight reduction
by bariatric surgery techniques have been increasingly used
to prevent and reduce its comorbidities [2, 3].
Gut hormone profiles following bariatric surgery favor
an anorectic state, improve metabolic parameters (i.e.,
insulin resistance, glycemic control, dyslipidemia), convey
appetite reduction, and facilitate long-term changes in body
weight (BW) [4, 5].
The only known peripheral hormone with orexigenic
action, the gastroenteric peptide ghrelin, apparently coun-
terbalances energy homeostasis in opposition to multiple
anorectic signals (NPY, AGRP, POMC, GABA, etc.) [6].
Ghrelin, which predominantly targets the same neuronal
structures on which leptin and PYY [7–9] exert their action,
even induces a positive energy balance resulting in
increased adiposity. Since ghrelin is secreted in response
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to caloric restriction and its expression and secretion are
rapidly suppressed by food intake, it has been proposed to
play a physiological role in meal initiation as the
endogenous “hunger hormone.” [10]
The medical literature reveals a lack of consensus
regarding serial changes in ghrelin levels after gastric
bypass. Hence, several studies have shown that Roux-
en-Y Gastric Bypass (RYGBP) in human patients causes a
decrease in circulating levels of ghrelin [11–14]. Converse-
ly, other authors report unchanged [15] or even increased
ghrelin levels after bariatric surgery. [16]
Furthermore, a recently developed clinically relevant rat
model of RYGBP claims that postoperative weight loss is
correlated with the magnitude of the decrease in circulating
ghrelin levels. This correlation provides the strongest
evidence to date that altered ghrelin signaling contributes
to weight loss after this operation [17].
These contradictory results tend to suggest that regula-
tion of this hormone is complex and subject to genetic and
other patient-related miscellaneous factors.
The present study was undertaken to: (1) measure
ghrelin fasting levels in a cohort of female subjects in
conditions of stable body weight and with a wide range of
body mass index (BMI), (2) to analyze the postoperative
evolution of ghrelin levels in the function of the concom-
itant modifications of the BMI, and (3) to compare the
postoperative ghrelin values with those measured in weight-
stable subjects having similar age and BMI.
Materials and Methods
A cohort of 115 females (age 40±1 years old, range 18–64)
participated in the study which had been previously
approved by the local Ethical Committee. The subjects
were examined in conditions of stable body weight and
classified according to their BMI as normal body weight
(N=21; BMI<25 kg m−2), overweight (N=10; BMI 25–
29.9 kg m−2), obese (N=22; BMI 30–40 kg m−2), morbidly
obese (N=41; BMI 40–50 kg m−2), and massively obese
(N=21, BMI>50 kg m−2). The stability of body weight—
anamnestically established—was defined as no changes in
body weight greater than 5% of the actual body weight, in
the last 6 months. In these subjects, anthropometric
parameters as well as plasma ghrelin were measured in
fasting conditions. Among the 84 obese subjects, a
subgroup of 49 patients underwent a gastric bypass surgery
(RYGBP). In these patients, we evaluated both BMI and
fasting ghrelin at 3, 6, and 12 months after surgery. At each
time point, the patients were classified according to their
actual BMI, as was done in stable body weight conditions.
Fasting plasma ghrelin was assessed by commercial kit
(Phoenix Pharmaceutical, CA, USA).
Simple regression analysis, factorial analysis of variance
(ANOVA), or ANOVA for repeated measurements was
utilized for statistical analysis. The percent of excess BMI
lost (%EBL) and the percent of excess weight loss (%EWL)
were calculated according to the formula in a recent report
[18, 19]. The change in body weight (%Δ body weight)
was calculated as preoperative BW minus postoperative
BW divided by preoperative BW times 100.
All p values were two-tailed with 0.05 specified as
statistical significance. All statistical analyses were per-
formed with statistical software (SPSS version 10.0 for
Windows, SPSS, Chicago, IL, USA).
Results
Plasma ghrelin levels (pg/ml) as measured in different BMI
classes (kg/m2) both in stable body weight conditions and
during gastric-bypass-induced body weight loss appear
illustrated in Table 1. As shown, the three obese subgroups
showed fasting ghrelin levels significantly lower than those
measured in both normal body weight and overweight
subjects. No significant differences were observed within
the three obese groups.
The 49 surgically treated patients were further divided
into subgroups according to the BMI that they had reached
at each postoperative time point.
Three months after surgery, 35 patients out of 49 were
classified in the obese group and 14 in the morbidly obese
group. No statistically significant differences were observed
in mean plasma ghrelin between these two groups.
Six months after surgery, eight patients had reached a
BMI of overweight; 34 were classified as obese while seven
remained in the morbidly obese group. A significant
difference was observed in ghrelin values between the
overweight and morbidly obese groups (458±57 vs. 270±
33 pg/ml, respectively; p<0.02).
One year after surgery, patients having attained a normal
body weight displayed the highest ghrelin levels (566±
64 pg/ml, n=5). This value was significantly different from
the ones measured in all the other groups (p<0.05 vs.
overweight group; p<0.02 vs. obesity group; and p<0.004
vs. morbidly obese group) but otherwise similar to ghrelin
levels in stable body weight normal-weight (N<25)
individuals (502±37 pg/ml).
By using factorial ANOVA, no significant differences
were found between ghrelin values measured postopera-
tively in the different BMI classes and plasma ghrelin
measured in the corresponding BMI classes in conditions of
stable body weight (Table 1, follow vertical arrows).
Figure 1a depicts a significant robust negative relation-
ship between BMI and ghrelin levels (r2=0.88; p<0.0002),
in stable body weight conditions, whereas Fig. 1b replicates
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the identical significant negative relationship using postop-
erative BMI and ghrelin values (r2=0.87; p=0.0002).
The simultaneous serial changes in BMI, ghrelin, and
percentage of excess weight loss (EWL) occurring in the 49
patients submitted to RYGBP are depicted in Table 2. As
shown, RYGBP resulted in a 38.5% and 55% excess weight
loss at 6 (p<0.001) and 12 months (p<0.0001), respective-
ly. Simultaneously, ghrelin levels increased significantly by
19% and 22.8% at 6 (p<0.0001) and 12 months (p<
0.0001), respectively. Finally, BMI decreased by 24.3% and
31.1% at 6 and 12 months, respectively.
Discussion
The most novel finding in our study is the persistent inverse
correlation between fasting ghrelin levels and BMI along the
12 months following RYGBP. In our series, fasting total
ghrelin levels increased by 22.8% in the 12 months following
RYGBP when compared to baseline values. Besides, no
evidence was found that RYGBP surgery had an effect on
fasting total ghrelin levels, independent of weight loss.
Our results (Table 1, Fig. 1a,b) disclose a significant
inverse correlation between fasting ghrelin levels and BMI
across a wide BMI range (from normal body weight to
morbidly obese patients) in agreement with previous reports
[20, 21] stating that the circulating concentration of ghrelin
is determined by body weight in first instance.
All current bariatric surgeries result in weight loss of
large magnitude, correction of comorbidities, and excellent
short- and long-term outcomes [3, 22, 23]. Together with
the spectacular weight loss seen in bariatric surgery,
endocrine changes take place, particularly after laparoscop-
ic RYGBP (LRYGB).
Since ghrelin seems to play a key role in the complicated
energy balance loop, it is logical to hypothesize that its
Table 1 Plasma ghrelin levels (pg/ml) as measured in different BMI classes (kg/m2) both in stable body weight conditions and during gastric-
bypass-induced body weight loss
   BMI classes          <25 kg/m2                             25-30 kg/m2                        30-40 kg/m2                        40-50 kg/m2                     >50 kg/m2                
   
  BMI           ghrelin 
(kg/m2)        (pg/ml)
   
  BMI           ghrelin     
(kg/m2)        (pg/ml)
   
  BMI            ghrelin
(kg/m2)         (pg/ml)
   
  BMI            ghrelin
(kg/m2)         (pg/ml)
  BMI           ghrelin
(kg/m2)        (pg/ml)
Stable body weight 21.5±0.4      502±37
            (n=21)
27.6±0.5      444±61
            (n=10) 
35.2±0.7      346±30
           (n=22) **
,
 *** **
,
 ***
44.1±0.4      324±12
            (n=41)   
53.7±0.8      302±15
(n=21**, *****) 
3 months postop. 35.4±0.4      347±20
           (n=35)
44.4±0.7      307±39
            (n=14)
6 months postop. 29.1±0.2     458±57
           (n=8)
34.1±0.5      392±25
            (n=34) 
43.2±0.5      270±33
            (n=7) ***
****
12 months postop. 24.0±0.4      566±64
             (n=5)
27.6±0.3      410±38
             (n=17) *
34.1±0.5      386±30
              (n=22) *
42.4±0.6       266±52
              (n=4) 
*p<0.04 or 0.01 (factorial ANOVA), significantly different from BMI<25 (normal body weight); **p<0.2008 (factorial ANOVA), significantly
different from BMI<25 (normal body weight); ***p<0.04 or 0.01 (factorial ANOVA), significantly different from BMI 25–30 (overweight);
****p<0.005 (factorial ANOVA), significantly different from BMI<25 (normal body weight); *****p<0.005 (factorial ANOVA), significantly
different from BMI 25–30 (overweight)
Fig. 1 a Scatterplot between
BMI and ghrelin levels in stable
body weight conditions (base-
line). R: Pearson’s coefficient.
b Scatterplot between BMI and
ghrelin levels postoperatively.
R: Pearson’s coefficient
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changes after surgery could affect the success of the
operation.
As a result of bariatric surgery, energy intake is markedly
decreased; patients experience decreased hunger, early
fullness, and enhanced satiety. Moreover, the ingested food
bypasses important parts of the digestive system because of
the decreased food transit time, resulting in partial
malabsorption and a total negative energy balance. [24, 25].
Postoperatively, ghrelin levels depend on the functional
integrity of the remaining fundus, the size of the gastric pouch
[26, 27], the length of the Roux limb or biliopancreatic limb
[16, 28], and/or the adaptive responses of body weight
homeostasis [10, 20, 29, 30]. Because ghrelin levels have
been shown to be low after LRYGB in some studies [20, 30,
31–36], it has been proposed that lower ghrelin levels may
contribute to the success of some surgical weight loss
procedures, including LRYGB [14, 15, 20] and possibly
laparoscopic adjustable gastric banding [30]. However, data
have been inconsistent [10, 12, 15, 16, 25, 37]. Cummings et
al. [10, 20], in a cross-sectional study, was the first to report
low total plasma ghrelin concentrations in five obese patients
9–31 months after LRYGB, who were still obese, compared
with those in a group of matched obese controls.
Our bariatric population disclosed a marked decrease in
BMI in agreement with the majority of LRYGBP prospec-
tive studies [3, 22, 23]. One would expect the massive
decrease in BMI achieved with these surgeries to trigger an
elevation in ghrelin levels. Noteworthy, four out of the 13
studies of patients who underwent LRYGB [15, 16, 37, 38]
showed an increase in ghrelin levels after surgery whereas
nine have shown a paradoxical reduction in plasma ghrelin
levels. It is possible that these different outcomes depend
on how and when the postoperative samples were taken (i.
e., whether subjects were actively losing weight or had
achieved a stable lower BMI), as well as the differences in
surgical techniques across centers. Thus, it is difficult to
reconcile the existing data and formulate a conclusion as to
the effect of LRYGB on ghrelin release.
Our bariatric population disclosed postoperative ghre-
lin values (see Table 2) in agreement with those reported
by Holdstock et al. [16], who, in a prospective study of 66
patients, reported increased ghrelin levels at 6 (+44%)
and 12 (+62%) months after LRYGB compared to the
preoperative levels. Interestingly, postoperative ghrelin
increments in our series were more modest (+19% and
22.8%, respectively). On the contrary, excess weight loss
was more prominent at 6 and 12 months postoperatively
(−38.5%, −55.5%, ours, respectively vs. −22%, −30%,
Holdstock, respectively). Circulating ghrelin levels in our
bariatric patients continue to be primarily produced by the
disconnected stomach and the control of the ghrelin-
producing endocrine cells seems to remain unaltered.
Thus, it is the lowered caloric intake and the resulting
weight loss rather than RYGBP surgery that affects
ghrelin levels. These changes are all related to changes
in BMI and reflect the new state of energy balance
achieved.
Last but not least, fasting ghrelin values in our series are
indistinguishable between stable body weight and actively
losing weight participants provided they share the same
BMI category (Table 1, vertical arrows), stressing the
underlying specific influence of BMI on fasting ghrelin
values, in agreement with previous reports [20, 21].
Should we still pay attention to ghrelin in the context of
bariatric surgery? The majority of authors agree upon the
fact that ghrelin is an important determinant of energy
homeostasis, a peripherally secreted orexigenic hormone
acting in key central pathways, with measurable levels
demonstrating meal-to-meal variation. Noteworthy, to our
knowledge, no study to date has demonstrated that ghrelin
levels postoperatively are predictors of success in patients
after LRYGB [36].
Our study limitations include lack of postprandial
ghrelin levels and of measurements of the active form—
acylated ghrelin levels [31, 39]. In future studies, it should
also be important to investigate ghrelin levels in parallel
satiety scales, as well as simultaneous evaluation of other
gut hormones interfering with appetite control such as
glucagon-like peptide 1, gastric inhibitory peptide, PYY,
and cholecystokinin, among others.
Table 2 Evolution of BMI (kg/m2) and fasting ghrelin (pg/ml), measured before, 3, 6, and 12 months after surgery (RYGBP), in a subgroup of 49
obese subjects submitted to a gastric bypass
BMI (kg/m2) Ghrelin (pg/ml) %EWL
Before surgery 45.7±0.8 329±15 0
3 months postop. 38.0±0.7* 338±19 38.5±1.3
6 months postop. 34.6±0.7* 390±22** 55.5±2.0
12 months postop. 31.5±0.7* 404±23* 71.4±2.9
*p<0.0001, significantly different from preoperative values (ANOVA for repeated measurements); **p<0.001, significantly different from
preoperative values (ANOVA for repeated measurements)
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